scPharmaceuticals: FUROSCIX®*(furosemide) 80mg/10mL for subcutaneous administration Commercial Day: An Investigational Treatment for Heart Failure Patients
|DATE:||July 13, 2022|
|TIME:||10:00 AM EDT|
About The Event
The commercial day will feature presentations from Key Opinion Leaders Daniel Robert Bensimhon, MD (HF & Mechanical Circulatory Support Program at Cone Health) and James T. Kenney (President of JTKENNEY, LLC). Dr. Bensimhon will discuss the current treatment landscape and unmet medical need in treating adult patients with New York Heart Association (NYHA) Class II and Class III heart failure. James Kenney will provide insights from the payer perspective and discuss the high costs associated with treating heart failure patients.
The scPharmaceuticals leadership team will discuss their potential heart failure treatment solution FUROSCIX®, a proprietary formulation of furosemide that is designed to be administered by subcutaneous infusion via a wearable on-body, drug delivery system, and how it can reduce healthcare costs by enabling the management of heart failure patients both pre-admission and post-discharge, if approved.
A live question and answer session will follow.